Literature DB >> 22846521

Disorders of sex development: neonatal diagnosis and management.

Françoise Paris, Laura Gaspari, Pascal Philibert, Laurent Maïmoun, Nicolas Kalfa, Charles Sultan.   

Abstract

The disorders of sex development (DSD) refer to the insufficient virilization of the external genitalia of a 46,XY fetus or the excessive virilization of those of the 46,XX fetus. Some of these disorders are associated with karyotype abnormalities. DSD arise from abnormal gonadal determination or sex differentiation, as in the case of the abnormal testosterone synthesis or androgen insensitivity of 46,XY DSD. The impact of environmental endocrine disrupting chemicals during fetal life requires further investigation. The basic investigations should include SRY gene sequencing and measurement of 17-hydroxyprogesterone, anti-Mullerian hormone, and testosterone. Choosing the sex of rearing is difficult and the decision must be made by an experienced multidisciplinary team.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22846521     DOI: 10.1159/000326631

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  3 in total

1.  Early Prenatal Phthalate Exposure, Sex Steroid Hormones, and Birth Outcomes.

Authors:  Sheela Sathyanarayana; Samantha Butts; Christina Wang; Emily Barrett; Ruby Nguyen; Stephen M Schwartz; Wren Haaland; Shanna H Swan
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 6.134

2.  46,XY disorder of sex development due to 17-beta hydroxysteroid dehydrogenase type 3 deficiency: a plea for timely genetic testing.

Authors:  Chelsey Grimbly; Oana Caluseriu; Peter Metcalfe; Mary M Jetha; Elizabeth T Rosolowsky
Journal:  Int J Pediatr Endocrinol       Date:  2016-06-15

3.  Clinical profile of 93 cases of 46, XY disorders of sexual development in a referral center.

Authors:  Bianca Costa Mota; Luciana Mattos Barros Oliveira; Renata Lago; Paula Brito; Ana Karina Canguçú-Campinho; Ubirajara Barroso; Maria Betânia Pereira Toralles
Journal:  Int Braz J Urol       Date:  2015 Sep-Oct       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.